Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tony echols who wrote (411)	4/14/1997 3:05:00 PM
From: Miles Rhyne Hoffman, CFA	of 849

Chugai gets rights to prostate cancer check test...Friday March 28 2:58 AM EST TOKYO, March 28 (Reuter) - Chugai Pharmaceutical Co Ltd 4519.T said on Friday that it has obtained the worldwide rights to a measuring system that can diagnose prostate cancer from EG&G Wallac of Finland. The system assesses free prostate-specific antigen (PSA) and complex PSA levels in the bloodstream using a manually operated measuring device, the company said in a statement. EG&G Wallac, a wholly owned subsidiary of EG & G Inc of the United States, acquired a patent on the system in Europe and the United States in 1996. The patent is also expected to receive approval in Japan. The annual global market for PSA measuring systems is estimated to be about $400 million, the statement said. Chugai also said it has set up a wholly owned subsidiary in the diagnostics business, Chugai Diagnostics Science Co Ltd. The new firm is capitalised at 10 million yen and expected to start operating in October.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next